We claim:

1. A combination comprising a histamine-3 receptor inverse agonist and an acetylcholinesterase inhibitor; wherein the histamine-3 receptor inverse agonist is selected from the group consisting of:
N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide;
N-[4-(1-Cyclopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide; and
N-[4-(1-Isopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide;
or a pharmaceutically acceptable salt thereof.

2. The combination as claimed in claim 1, wherein the acetylcholinesterase inhibitor is selected from the group consisting of donepezil, rivastigmine and galantamine or a pharmaceutically acceptable salt thereof.

3. The combination as claimed in claim 1 or 2, wherein the histamine-3 receptor inverse agonist is N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof.

4. The combination as claimed in any one of claims 1 to 3, wherein the pharmaceutically acceptable salt of the histamine-3 receptor inverse agonist is selected from the group consisting of
N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride;
N-[4-(1-Cyclopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide tartrate; and
N-[4-(1-Isopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide tartrate.

5. The combination as claimed in any one of claims 1 to 4, wherein the histamine-3 receptor inverse agonist is N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride.

6. The combination as claimed in any one of claims 1 to 5, wherein the acetylcholinesterase inhibitor is donepezil or a pharmaceutically acceptable salt thereof.

7. The combination as claimed in any one of claims 1 to 6, wherein the acetylcholinesterase inhibitor is donepezil hydrochloride.

8. A combination comprising N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride and donepezil hydrochloride.

9. The combination as claimed in any one of claims 1 to 8, for use in therapy.

10. Use of the combination as claimed in any one of claims 1 to 8 in the manufacture of a medicament for the treatment of cognitive disorders in a patient.

11. The use as claimed in claim 10, wherein the cognitive disorder is selected from the group consisting of Alzheimer's disease, schizophrenia, Parkinson's disease, Lewy body dementia, vascular dementia, frontotemporal dementia, Down syndrome and Tourette's syndrome.

12. A compound, N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl) acetamide or a pharmaceutically acceptable salt thereof for use in combination with acetylcholinesterase inhibitor for use in therapy.

13. The compound for use as claimed in claim 12, as an adjunct treatment for Alzheimer's disease in a patient on stable treatment with acetylcholinesterase inhibitor.

14. The compound for use as claimed in the claim 12 or claim 13, wherein the acetylcholinesterase inhibitor is selected from the group consisting of donepezil, rivastigmine and galantamine or a pharmaceutically acceptable salt thereof.

15. Use of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof and an acetylcholinesterase inhibitor in the manufacture of a medicament for the treatment of Alzheimer's disease in a patient.

16. Use of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of Alzheimer's disease in a patient on stable treatment with an acetylcholinesterase inhibitor.

17. The use as claimed in claim 15 or claim 16, wherein the pharmaceutically acceptable salt of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide is N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride.

18. The use as claimed in any one of claims 15 to 17, wherein the acetylcholinesterase inhibitor is selected from the group consisting of donepezil, rivastigmine and galantamine or a pharmaceutically acceptable salt thereof.

19. The use as claimed in any one of claims 15 to 18, wherein 0.1 mg to 100 mg of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof is to be administered to the patient per day.

20. The use as claimed in any one of claims 15 to 19, wherein 0.1 mg to 60 mg of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof is to be administered to the patient per day.

21. The use as claimed in any one of claims 15 to 20, wherein 0.1 mg to 30 mg of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof is to be administered to the patient per day.

22. The use as claimed in any one of claims 18 to 21, wherein 1 mg to 30 mg of donepezil, or a pharmaceutically acceptable salt thereof is to be administered to the patient per day.

23. A pharmaceutical composition comprising the combination as claimed in any one of claims 1 to 8, and pharmaceutically acceptable excipients or a combination thereof.

24. The pharmaceutical composition as claimed in claim 23, for use in therapy.

25. Use of the pharmaceutical composition as claimed in claim 23 in the manufacture of a medicament for the treatment of cognitive disorders selected from the group consisting of Alzheimer's disease, schizophrenia, Parkinson's disease, Lewy body dementia, vascular dementia, frontotemporal dementia, Down syndrome and Tourette's syndrome.

26. The pharmaceutical composition as claimed in claim 23, wherein the histamine-3 receptor inverse agonist is N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof and is present in an amount of 0.1 mg to 100 mg.

27. The pharmaceutical composition as claimed in claim 23 or claim 26, wherein the histamine-3 receptor inverse agonist is N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof and is present in an amount of 0.1 mg to 60 mg.

28. The pharmaceutical composition as claimed in any one of claims 23, 26 and 27, wherein the histamine-3 receptor inverse agonist is N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof and is present in an amount of 0.1 mg to 30 mg.

29. The pharmaceutical composition as claimed in any one of claims 23 and 26 to 28, wherein the acetylcholinesterase inhibitor is donepezil or a pharmaceutically acceptable salt thereof and is present in an amount of 2 mg to 30 mg.

30. The use as claimed in claim 15, wherein the N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof is to be administered to the patient by oral, nasal, local, dermal or parenteral routes.

31. The use as claimed in claim 15, wherein the N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof is to be administered to the patient one to three times per day, one to three times per week or one to three times per month.